Navigation Links
Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
Date:1/22/2009

lood sugar. Initial clinical studies of trodusquemine in obese and overweight subjects has provided early indicators of weight loss and improved glucose control. These results confirm previous work in animal models which demonstrated significant weight loss without metabolic rebound, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as
'/>"/>

SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
2. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
3. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
4. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
5. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
6. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
7. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
10. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
(Date:8/29/2014)... SPRING, Md. , Aug. 29, 2014  United ... that the U.S. District Court for the District of ... its favor in the company,s case against Sandoz, Inc. ... Judge Peter Sheridan ruled that U.S. Patent ... Inc., and enjoined Sandoz from marketing its generic product ...
(Date:8/29/2014)... PITTSBURGH , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage ... at the Australian and New Zealand Forensic Science ... Forensic Sciences in Adelaide, Australia ... discussion concerning the advancements that hyperspectral imaging can ... Jeffrey Beckstead , Director of Product Development ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... treatment for spine tumorsLAS VEGAS, Feb. 22 For orthopaedic ... is a personal as well as a professional mission. Her ... still remembers the incredible pain her cousin experienced when the ... Dr. Keyak and her colleagues at the University of ...
... and Efficacy Results Support Follow-on NEST-3 TrialCARLSBAD, Calif., ... by PhotoThera, Inc., transcranial laser therapy (TLT) for ... onset demonstrated improved outcomes for patients, but did ... post-hoc analysis in patients who had moderate to ...
Cached Medicine Technology:Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads 2Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads 3Results of NeuroThera Effectiveness and Safety Trial - 2 (NEST-2) Presented at International Stroke Conference 2009 2
(Date:8/30/2014)... FL (PRWEB) August 30, 2014 McLeod's ... full service auto repair shop with strong ties to the ... Family is happy to announce they have been chosen by ... one pick for auto repair. , Tim McLeod’s father, ... Auto Service sixty years ago. Although his son, Tim runs ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 As 500 Zoloft ... defect when give to pregnant mothers, Wright & Schulte LLC ... Cynthia M. Rufe. The remand in the Zoloft ... of 18 states and are involved in one SSRI ... to have their Zoloft birth defect lawsuit sent back to ...
(Date:8/30/2014)... 2014 Barton Associates, an industry leading ... tenens company , announces a new office location in ... Associates is headquartered in Peabody, MA, with additional staffing ... Jupiter, FL. , Barton Associates decided to ... for healthcare providers. The United States is in the ...
(Date:8/30/2014)... Celebrating its 25th year, Recovery Month ... the fact that millions of Americans lives have ... addiction and mental health disorders. Every September ... programs and other community groups to recognize the ... The rallying theme for Substance Abuse and ...
(Date:8/30/2014)... August 2014: The first expert consensus on ventricular ... current evidence on the diagnosis and management of ... from three continents. , The "EHRA/HRS/APHRS Expert Consensus ... EP Europace (1). It was written ... of the European Society of Cardiology (ESC), the ...
Breaking Medicine News(10 mins):Health News:McLeod's Sunset Park Auto Service Celebrates 60 Years Honored with Best of South Tampa 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 3Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 4Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 5Health News:Barton Associates Announces New Office Location in Austin, TX 2Health News:September is National Recovery Month: What the Connecticut Community for Addiction Recovery (CCAR) Wants You to Know 2Health News:September is National Recovery Month: What the Connecticut Community for Addiction Recovery (CCAR) Wants You to Know 3Health News:First expert consensus on ventricular arrhythmias published 2Health News:First expert consensus on ventricular arrhythmias published 3
... heroes fighting for treatment, ARLINGTON, Va., Dec. ... Advocacy Center today announced that Karen,Gherardini (Illinois), Janice ... annual Torrey Advocacy Commendation. The,Treatment Advocacy Center (TAC) ... to the timely and effective treatment of,severe mental ...
... 17 Many medications,reduce the risk of bone ... used drugs - bisphosphonates- have not been proven ... funded by the Agency for,Healthcare Research and Quality ... Human Services., The AHRQ report compared the ...
... changes to the S&P 500 and S&P SmallCap 600:, -- Range ... ) in the S&P 500 after the close of ... private in a deal expected to close on or about ... SLXP ) will replace Coherent Inc. (Nasdaq: COHR ...
... December 17, 2007 Nationally recognized Attention Deficit Hyperactivity Disorder ... speaking tour to discuss the symptoms of ADHD in adults ... the life of an adult living with this disorder. ... adults, or 9.2 million adults across the U.S. based on ...
... tailor prevention messages, according to a report in the ... JAMA/Archives journals. , Nearly 2 million Americans tan indoors ... the United States having doubled to nearly 30 million ... the article. Evidence that indoor tanning poses a serious ...
... surgery technique appears promising for the removal of cancer ... the December issue of Archives of OtolaryngologyHead & Neck ... trying to remove tonsils of patients with cancer through ... to background information in the article. If the cancer ...
Cached Medicine News:Health News:Treatment Advocacy Center Honors Three Grassroots Mental Illness Advocates 2Health News:Many Osteoporosis Medications Prevent Fractures, But None Is Proven Best 2Health News:Many Osteoporosis Medications Prevent Fractures, But None Is Proven Best 3Health News:Standard & Poor's Announces Changes to U.S. Indices 2Health News:Standard & Poor's Announces Changes to U.S. Indices 3Health News:Adult ADHD significantly impacts on social, financial and personal aspects of life 2Health News:Adult ADHD significantly impacts on social, financial and personal aspects of life 3Health News:Classifying indoor tanning behaviors can help physicians tailor prevention messages 2Health News:Robotic device appears useful for surgical removal of cancer involving the tonsils 2
... Lightweight mechanical brace for functional knee ... or LCL instabilities. Unique hinge design ... load on ACL. Does not require ... injured or repaired knee without migration ...
... Orthosis Custom-fitted static-progressive orthosis ... Goniometer version has calibrated ... metal contacts skin. Includes ... bag. One size fits ...
... Polyamide Hinge Wraparound design can ... fit. Multilock polyamide hinge prevents ... extension can be set for ... level. Provides medial/lateral support during ...
... the dynamic way to manage a contracture. ... effective in reducing contractures. Full ROM is ... therapies. Can also be used as a ... and soft tissue contractures. Use where ROM ...
Medicine Products: